Literature DB >> 17388947

Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells.

Volker Schick1, Michael Majores, Gudrun Engels, Wolfgang Hartmann, Christian E Elger, Johannes Schramm, Susanne Schoch, Albert J Becker.   

Abstract

Balloon cells of distinct focal cortical dysplasias type IIb (FCD(IIb)) and giant cells of cortical tubers in tuberous sclerosis (TSC) constitute neuropathological hallmarks and cytological similarities. In TSC, frequent mutations in the TSC1 or TSC2 genes result in mTOR-signaling activity. Here, we addressed whether Pi3K-pathway activation differentiates balloon cells from giant cells. We used immunohistochemistry with antibodies against p-PDK1 (S241), p-Akt (S473), p-tuberin (T1462), p-p70(S6K) (T389), p-p70(S6K) (T229) and phalloidin-staining to analyze stress fiber formation in balloon cells of FCD(IIb) (n = 23) compared with cortical tuber giant cells (n = 5) and adjacent normal CNS tissue as control. We have further established an in vitro assay to assess potential phosphorylation between Akt and S6. We observed phosphorylated (p-)PDK1, p-Akt, p-tuberin, and p-p70-kDa S6-kinase (p-p70(S6K); residue T229) in balloon cells, whereas giant cells showed only equivalent levels of p-tuberin, p-p70(S6K) and stress fibers. Furthermore, Pi3K-cascade activity in balloon cells may reflect pathway "cross-talk". An in vitro assay revealed S6, a major target of p70(S6K), to increase phosphorylation of Akt. Our data suggest recruitment of different Pi3K-cascade factors in the molecular pathogenesis of giant cells in cortical tubers vs. balloon cells in FCD(IIb) and provides new implications for the development of treatment strategies for these cortical malformations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388947     DOI: 10.1111/j.1750-3639.2007.00059.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  23 in total

1.  Down-Regulated Expression of Liver X Receptor beta in Cortical Lesions of Patients with Focal Cortical Dysplasia.

Authors:  Xin Chen; Lukang Wang; Bing Chen; Jiong Yue; Gang Zhu; Chunqing Zhang; Shiyong Liu; Hui Yang
Journal:  J Mol Neurosci       Date:  2016-07-20       Impact factor: 3.444

2.  PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia.

Authors:  Laura A Jansen; Ghayda M Mirzaa; Gisele E Ishak; Brian J O'Roak; Joseph B Hiatt; William H Roden; Sonya A Gunter; Susan L Christian; Sarah Collins; Carissa Adams; Jean-Baptiste Rivière; Judith St-Onge; Jeffrey G Ojemann; Jay Shendure; Robert F Hevner; William B Dobyns
Journal:  Brain       Date:  2015-02-25       Impact factor: 13.501

Review 3.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

4.  Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling.

Authors:  Fuyi Chen; Joel Rosiene; Alicia Che; Albert Becker; Joseph LoTurco
Journal:  Development       Date:  2015-09-23       Impact factor: 6.868

Review 5.  Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2007-08-28       Impact factor: 5.864

Review 6.  Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.

Authors:  Michael Wong
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

Review 7.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

8.  The enlarging spectrum of focal cortical dysplasias.

Authors:  Peter B Crino
Journal:  Brain       Date:  2015-06       Impact factor: 13.501

9.  Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.

Authors:  Delia M Talos; Hongyu Sun; Bela Kosaras; Annelise Joseph; Rebecca D Folkerth; Annapurna Poduri; Joseph R Madsen; Peter M Black; Frances E Jensen
Journal:  Ann Neurol       Date:  2012-03-23       Impact factor: 10.422

10.  Contribution of tumor heterogeneity in a new animal model of CNS tumors.

Authors:  Fuyi Chen; Albert J Becker; Joseph J LoTurco
Journal:  Mol Cancer Res       Date:  2014-02-05       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.